SCHEMBL22866493

SCHEMBL22866493

Cc1[nH]c(=O)c2c(C#N)cc(C(F)(F)F)cc2c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.38
▸ HPGD P15428 6/20 0.38
▸ ALDH1A1 P00352 5/20 0.38
▸ GAA P10253 5/20 0.38
▸ GLA P06280 4/20 0.38
▸ TP53 P04637 1/20 0.38
▸ GALR3 O60755 1/20 0.36
▸ PDE3B Q13370 3/20 0.35
▸ PDE3A Q14432 3/20 0.35
▸ PDE5A O76074 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ PTGS1 P23219 1/20 0.35
▸ PDE4A P27815 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ PDE4C Q08493 1/20 0.35
▸ PDE4D Q08499 1/20 0.35
▸ GPBAR1 Q8TDU6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29559825 1.00 KDM4E (0.38) KDM4EHPGDALDH1A1GAAGLA
SCHEMBL22866492 0.75 KDM4E (0.49) KDM4EHPGDALDH1A1GAAGLA
SCHEMBL29559896 0.75 KDM4E (0.49) KDM4EHPGDALDH1A1GAAGLA
SCHEMBL22858208 0.73 CDK4 (0.41) KDM4EHPGDALDH1A1GAAGLA
SCHEMBL16740934 0.67 KDM4E (0.49) KDM4EHPGDALDH1A1GAAGLA
SCHEMBL23502945 0.67 AR (0.42) AR
SCHEMBL27614015 0.65 CYP11B1 (0.40) AR
SCHEMBL13280215 0.64 KDM4E (0.49) KDM4EHPGDALDH1A1GAAGLA
SCHEMBL29560609 0.64 PARP1 (0.51) ALDH1A1EIF4EBP1
SCHEMBL28072862 0.64 IP6K1 (0.55) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114269756-B 4-Oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds that inhibit EIF4E 效应疗法股份有限公司 2024-05-14 — — CN disclosed
US-20230108594-A1 EIF4E-INHIBITING COMPOUNDS AND METHODS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2023-04-06 — — US disclosed
EP-3994139-A1 EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS Effector Therapeutics Inc. (US) 2022-05-11 — — EP disclosed
CN-114269756-A 4-oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds inhibiting EIF4E 效应疗法股份有限公司 2022-04-01 — — CN disclosed
US-11286268-B1 EIF4E-inhibiting compounds and methods EFFECTOR THERAPEUTICS, INC. (US) 2022-03-29 — — US disclosed
WO-2021003157-A1 EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS EFFECTOR THERAPEUTICS, INC. (US) 2021-01-07 — — WO disclosed
WO-2021003157-A1 EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS EFFECTOR THERAPEUTICS, INC. (US) 2021-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11286268-B1 EIF4E-inhibiting compounds and methods EIF4E, EIF4EBP1, EIF4A1 KDM4E 393/4885HPGD 4854/4885ALDH1A1 4794/4885
US-20230108594-A1 EIF4E-INHIBITING COMPOUNDS AND METHODS EIF4E, EIF4EBP1, EIF4A1 KDM4E 393/4885HPGD 4854/4885ALDH1A1 4794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback